Your Health, We Care
Release date: 2026-01-28 17:43:47 Recommended: 11
Remission is the primary treatment goal for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
Approximately one in five patients achieve complete remission plus complete remission with partial hematologic recovery (CR + CRh) with Revuforj.
In clinical trials, 21% of patients (22 out of 104) achieved complete remission (CR) or complete remission with partial hematologic recovery (CRh).
Among the 22 patients who achieved CR + CRh:
Some patients responded as early as one month after treatment initiation.
Half of the patients achieved remission within the first 2 months of treatment (the median time to CR + CRh was 1.9 months; range: 0.9 to 5.6 months), and half had a remission duration of more than 6.4 months.
Before administration, must inform your healthcare provider of all your health conditions if you have the following:
A history of any cardiac disease, including long QT syndrome.
Been advised of low blood potassium or magnesium levels.
Are pregnant or planning to become pregnant.
Are breastfeeding or planning to breastfeed.
Revuforj may cause fetal harm. For females of reproductive potential, healthcare providers will perform a pregnancy test within 7 days prior to the initiation of Revuforj treatment. If you become pregnant or suspect pregnancy during Revuforj treatment, inform your healthcare provider immediately.
Females of reproductive potential should use effective contraceptive measures during Revuforj treatment and for 4 months after the last dose.
Males with female partners of reproductive potential should also use effective contraceptive measures during Revuforj treatment and for 4 months after the last dose.
Consult your healthcare provider to select a suitable contraceptive method for this period.
